Objective To investigate the effect of Batroxobin in the treatment of sudden deafness with full frequency decline and its correlation with batroxobin sensitivity and coagulation function.Methods A retrospective analysis was conducted on 48 patients with sudden deafness and full frequency decline from January 2019 to February 2021 in our hospital. According to the changes of fibrinogen, the patients were divided into sensitive group and non-sensitive group. It was detected for the coagulation function including activated partial thrombin time (APTT), prothrombin time (PT), thrombin time (TT) and fibrinogen (FIB), and the changes of pure tone hearing threshold before and after treatment.Results (1) The total effective rate of 48 patients was 75.0%, including 72.4% for flat type, 78.9% for total deafness type, 85.71% for sensitive group and 60.0% for non-sensitive group. The effective rate of sensitive group was higher than that of non sensitive group, and the difference was statistically significant (P<0.05). (2) After treatment, FIB and APTT decreased and TT and PT increased in the sensitive group compared with before treatment, the difference was statistically significant (P<0.05);. After treatment, FIB decreased and TT increased in the non sensitive group compared with before treatment (P<0.05). After treatment, FIB in sensitive group was lower than that in non-sensitive group, TT and PT were higher than that in non sensitive group (P<0.05).Conclusions Batroxobin sensitivity is correlated with clinical therapeutic effect, which is mainly closely related to FIB, PT and TT, but not closely related to APTT. However, the body may reduce the risk of bleeding through the endogenous coagulation function of APTT. Batroxobin can enhance anticoagulant function, promote inner ear microcirculation, so that the anticoagulant, fibrinolysis and coagulation in a certain range of balance, good safety.